Home › Companies › CRVO

CervoMed

CRVO Rare disease Lead: Phase 3 ★ Read the deep dive → 10 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (5 active programs)

neflamapimod

VX-745

Small Molecule Target: p38α MAPK, p38 MAP kinase alpha, p38α, p38α MAP kinase, p38α kinase

Dementia with Lewy Bodies Phase 3 oral Vertex
Non-Fluent Variant Primary Progressive Aphasia Phase 2 oral Vertex
Stroke oral Vertex
Amyotrophic Lateral Sclerosis oral Vertex

neflamapimod

Small Molecule Target: p38α MAPK, p38α

Frontotemporal Dementia Phase 2 oral

Biotech Distilled coverage (10)

2026-06-18 UPDATE: CervoMed (CRVO) — Stopgap #2, A 2042 Patent, and a +71% Tape
2026-06-15 UPDATE: CervoMed (CRVO) — Same Data, Louder Font
2026-06-10 UPDATE: CervoMed (CRVO) - The Bag Got Secured. Sort Of.
2026-05-16 UPDATE: CervoMed (CRVO) - The Q1 10-Q Confirms the Countdown
2026-04-27 UPDATE: CervoMed (CRVO) - The Brain Scans Just Got Randomized 🔒 Paid
2026-03-29 UPDATE: CervoMed (CRVO) – Global Regulatory Blessing and Biological Proof at Roth 🔒 Paid
2026-03-21 UPDATE: CervoMed (CRVO) – The 6-Month Warning and the Smoking Gun in Copenhagen 🔒 Paid
2026-03-14 UPDATE: CervoMed (CRVO) – Annual Report Drops 🔒 Paid
2026-03-07 UPDATE: CervoMed (CRVO) – The Bad Batch Fix is In... 🔒 Paid
2025-12-31 CervoMed (CRVO): Scientific Due Diligence for Neflamapimod

Articles open on Substack. Some deep dives are subscriber-only.